CellAegis Devices

About CellAegis Devices

CellAegis Devices Inc., a Canadian medical device company founded in 2009, operates in the therapeutic devices sector, focusing on cardiovascular health. The company is headquartered in Toronto, Canada, with additional offices in Mississauga and Palo Alto. Its foundation stems from the clinical research of Dr. Andrew Redington and his colleagues at Toronto's Hospital for Sick Children. Drs. Andrew Redington and Christopher Caldarone are credited as the founders, leveraging their expertise in cardiology and cardiac surgery to address ischemia and reperfusion injury. The firm has successfully navigated several funding rounds, including a Series C round in March 2017 that raised $9.5 million to support clinical trials and regulatory submissions in the United States.

The core of CellAegis' business is the development and commercialization of the autoRIC® device, a non-invasive, automated system designed to deliver Remote Ischemic Conditioning (RIC). This therapy involves creating brief, controlled episodes of blood flow occlusion in a limb to activate the body's natural protective mechanisms against tissue damage caused by a lack of oxygen. The company's business model centers on selling this patented device to healthcare providers. The target market includes hospitals, emergency rooms, and ambulance services for the treatment of patients with acute and chronic cardiovascular conditions. Clients are primarily healthcare professionals treating adult patients undergoing cardiothoracic surgery, interventional cardiac procedures, or those experiencing a heart attack.

The autoRIC® device is a portable, cuff-based system placed on a patient's arm. It automates the RIC therapy by delivering four cycles of inflation and deflation, a process that takes less than 40 minutes. This automated delivery ensures consistency and reliability, which can be challenging with manual methods. The device is designed to be compatible with existing standard-of-care treatments, providing an adjunctive therapy to protect the heart and other organs from injury. The product has already received CE Mark certification in Europe and Health Canada approval for marketing, indicating it meets regional safety and performance standards. It is positioned as a solution to reduce complications like heart failure and kidney injury following cardiac events and procedures, aiming to improve patient outcomes and lower healthcare costs.